Cellular Reprogramming for Treating Blood Disorders
Author Information
Author(s): Laura J. Norton, Alister P. W. Funnell, Richard C. M. Pearson, Merlin Crossley
Primary Institution: University of New South Wales
Hypothesis
Can cellular reprogramming provide a new treatment for haemoglobinopathies like thalassaemia and sickle cell disease?
Conclusion
Cellular reprogramming can generate red blood cells in culture, offering a potential alternative to current treatments for haemoglobinopathies.
Supporting Evidence
- Cellular reprogramming can produce erythroid cells from fibroblasts.
- hiPSCs can generate red blood cells, but with reduced efficiency compared to hESCs.
- Transdifferentiation can directly convert fibroblasts into erythrocytes.
Takeaway
Scientists are trying to turn regular skin cells into blood cells to help people with blood diseases. This could make it easier to get the blood they need without the usual problems.
Methodology
The study discusses cellular reprogramming techniques and their application in generating erythroid cells from induced pluripotent stem cells (iPSCs) and transdifferentiation.
Potential Biases
Potential bias in the interpretation of results due to the reliance on specific cell lines and methodologies.
Limitations
The efficiency of generating erythroid cells from hiPSCs is lower compared to hESCs, and there are risks associated with the use of oncogenes in the reprogramming process.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website